Collection 1 (Apr 2017 - Aug 2021) Articles

Articles
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
Salim S Virani, Pamela B Morris, Anandita Agarwala, et al.
Journal:
J Am Coll Cardiol 2021 Aug 31;78(9):960-993

First published: August 31, 2021 DOI: 10.1016/j.jacc.2021.06.011
View
- Share
Articles
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies. With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L J Visseren, François Mach, Yvo M Smulders, et al.
Journal:
European Heart Journal August 2021; ehab484.

First published: August 30, 2021 DOI: 10.1093/eurheartj/ehab484
View
- Share
Articles
Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL
Marston NA, Giugliano RP, Park JG, et al.
Journal:
Circulation

First published: August 27, 2021 DOI: 10.1161/CIRCULATIONAHA.121.056536
View
- Share
Articles
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort
Christopher Blaum, Fabian J Brunner, Alina Goßling, et al
Journal:
Clin Ther. 2021 Aug 24;S0149-2918(21)00263-0

First published: August 27, 2021 DOI: 10.1016/j.clinthera.2021.07.019
View
- Share
Articles
Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition
Alexander R van Rosendael, Inge J van den Hoogen, Umberto Gianni, et al.
Journal:
JAMA Cardiol 2021 Aug 18

First published: August 18, 2021 DOI: 10.1001/jamacardio.2021.3055
View
- Share
Articles
Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
Vuorio A, Strandberg TE, Raal F, et al.
Journal:
Atheroscler Plus

First published: August 8, 2021 DOI: 10.1016/j.athplu.2021.08.001
View
- Share
Articles
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Schwartz GG, Szarek M, Bittner VA, et al.
Journal:
J Am Coll Cardiol 2021 Aug 3;78(5):421-433

First published: August 3, 2021 DOI: 10.1016/j.jacc.2021.04.102
View
- Share
Articles
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US for the GOULD Investigators
Christopher P. Cannon, MD1,2; James A. de Lemos, MD3 et al.
Journal:
JAMA Cardiol. 2021;6(9):1060-1068

First published: June 16, 2021 DOI: 10.1001/jamacardio.2021.1810
View
- Share
Articles
Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications A Prespecified Secondary Analysis of a Randomized Clinical Trial
G. Greg Peterson, Jia Pu, David J. Magid, et al.
Journal:
JAMA Cardiol. 2021;6(9):1050-1059

First published: June 2, 2021 DOI: 10.1001/jamacardio.2021.1565
View
- Share
Articles
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial
Rubino J, MacDougall DE, Sterling LR, et al.
Journal:
J Clin Lipidol

First published: May 28, 2021 DOI: 10.1016/j.jacl.2021.05.002
View
- Share
Articles
Comparison of the Effects of High-intensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study
Kim K, Bang WD, Han K, et al.
Journal:
J Lipid Atheroscler

First published: May 25, 2021 DOI: 10.12997/jla.2021.10.3.291
View
- Share
Articles
Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic
Chakraborty, A, Pang, J, Chan, DC, et al.
Journal:
Clin Cardiol 2021; 44: 805– 813

First published: May 6, 2021 DOI: 10.1002/clc.23607
View
- Share

1 2 3

Collection 1 (Apr 2017 - Aug 2021) Articles

Articles

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee

Salim S Virani, Pamela B Morris, Anandita Agarwala, et al.

Articles

Frank L J Visseren, François Mach, Yvo M Smulders, et al.

Articles

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Marston NA, Giugliano RP, Park JG, et al.

Articles

Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort

Christopher Blaum, Fabian J Brunner, Alina Goßling, et al

Articles

Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition

Alexander R van Rosendael, Inge J van den Hoogen, Umberto Gianni, et al.

Articles

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition

Vuorio A, Strandberg TE, Raal F, et al.

Articles

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz GG, Szarek M, Bittner VA, et al.

Articles

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US for the GOULD Investigators

Christopher P. Cannon, MD1,2; James A. de Lemos, MD3 et al.

Articles

Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications A Prespecified Secondary Analysis of a Randomized Clinical Trial

G. Greg Peterson, Jia Pu, David J. Magid, et al.

Articles

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Rubino J, MacDougall DE, Sterling LR, et al.

Articles

Comparison of the Effects of High-intensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study

Kim K, Bang WD, Han K, et al.

Articles

Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic

Chakraborty, A, Pang, J, Chan, DC, et al.

Articles

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee

Salim S Virani, Pamela B Morris, Anandita Agarwala, et al.

Share

Articles

Frank L J Visseren, François Mach, Yvo M Smulders, et al.

Share

Articles

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Marston NA, Giugliano RP, Park JG, et al.

Share

Articles

Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort

Christopher Blaum, Fabian J Brunner, Alina Goßling, et al

Share

Articles

Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition

Alexander R van Rosendael, Inge J van den Hoogen, Umberto Gianni, et al.

Share

Articles

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition

Vuorio A, Strandberg TE, Raal F, et al.

Share

Articles

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz GG, Szarek M, Bittner VA, et al.

Share

Articles

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US for the GOULD Investigators

Christopher P. Cannon, MD1,2; James A. de Lemos, MD3 et al.

Share

Articles

Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications A Prespecified Secondary Analysis of a Randomized Clinical Trial

G. Greg Peterson, Jia Pu, David J. Magid, et al.

Share

Articles

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Rubino J, MacDougall DE, Sterling LR, et al.

Share

Articles

Comparison of the Effects of High-intensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study

Kim K, Bang WD, Han K, et al.

Share

Articles

Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic

Chakraborty, A, Pang, J, Chan, DC, et al.

Share